Neuroinflammation is inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. In the central nervous system, including the brain and spinal cord, microglia are the resident innate immune cells that are activated in response to these cues. The CNS is typically an immunologically privileged site because peripheral immune cells are generally blocked by the blood–brain barrier (BBB), a specialized structure composed of astrocytes and endothelial cells. However, circulating peripheral immune cells may surpass a compromised BBB and encounter neurons and glial cells expressing major histocompatibility complex molecules, perpetuating the immune response. Although the response is initiated to protect the central nervous system from the infectious agent, the effect may be toxic and widespread inflammation as well as further migration of leukocytes through the blood–brain barrier.
- 1 Causes
- 2 Central Nervous System Immune Response
- 3 Peripheral Immune Response
- 4 Traumatic Brain Injury
- 5 Aging
- 6 Role in Neurodegenerative Disease
- 7 Role as a Therapeutic Target
- 8 References
- 9 External links
Neuroinflammation is widely regarded as chronic, as opposed to acute, inflammation of the central nervous system. Acute inflammation usually follows injury to the central nervous system immediately, and is characterized by inflammatory molecules, endothelial cell activation, platelet deposition, and tissue edema. Chronic inflammation is the sustained activation of glial cells and recruitment of other immune cells into the brain. It is chronic inflammation that is typically associated with neurodegenerative diseases. Common causes of chronic neuroinflammation include:
- Toxic metabolites
- Traumatic brain injury
- Air pollution
- Passive smoke
Central Nervous System Immune Response
Microglia are recognized as the innate immune cells of the central nervous system. Microglia actively survey their environment through, and change their cell morphology significantly in response to neural injury. Acute inflammation in the brain is typically characterized by rapid activation of microglia. During this period, there is no peripheral immune response. Over time, however, chronic inflammation causes the degradation of tissue and of the blood–brain barrier. During this time, microglia generate reactive oxygen species and release signals to recruit peripheral immune cells for an inflammatory response.
Astrocytes are glial cells that are the most abundant cells in the brain. They are involved in maintenance and support of neurons and compose a significant component of the blood–brain barrier. After insult to the brain, such as traumatic brain injury, astrocytes may become activated in response to signals released by injured neurons or activated microglia. Once activated, astrocytes may release various growth factors and undergo morphological changes. For example, after injury astrocytes form the glial scar composed of a proteoglycan matrix that hinders axonal regeneration.
Cytokines are a class of proteins that regulates inflammation, cell signaling, and various cell processes such as growth and survival. Chemokines are a subset of cytokines that regulate cell migration, such as attracting immune cells to a site of infection or injury. Various cell types in the brain may produce cytokines and chemokines such as microglia, astrocytes, endothelial cells, and other glial cells. Physiologically, chemokines and cytokines function as neuromodulators that regulate inflammation and development. In the healthy brain, cells secrete cytokines to produce a local inflammatory environment to recruit microglia and clear the infection or injury. However, in neuroinflammation cells may have sustained release of cytokines and chemokines which may compromise the blood–brain barrier. Peripheral immune cells are called to the site of injury via these cytokines and may now migrate across the compromised blood brain barrier into the brain. Common cytokines produced in response to brain injury include: interleukin-6 (IL-6), which is produced during astrogliosis, and interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), which can induce neuronal cytotoxicity. Although the pro-inflammatory cytokines may cause cell death and secondary tissue damage, they are necessary to repair the damaged tissue. For example, TNF-α causes neurotoxicity at early stages of neuroinflammation, but contributes to tissue growth at later stages of inflammation.
Peripheral Immune Response
The blood–brain barrier is a structure composed of endothelial cells and astrocytes that forms a barrier between the brain and circulating blood. Physiologically, this enables the brain to be protected from potentially toxic molecules and cells in the blood. Astrocytes form tight junctions and therefore may strictly regulate what may pass the blood–brain barrier and enter the interstitial space. After injury and sustained release of inflammatory factors such as chemokines, the blood–brain barrier may be compromised, becoming permeable to circulating blood components and peripheral immune cells. Cells involved in the innate and adaptive immune responses, such as macrophages, T Cells, and B Cells, may then enter into the brain. This exacerbates the inflammatory environment of the brain and contributes to chronic neuroinflammation and neurodegeneration.
Traumatic Brain Injury
Traumatic brain injury is brain trauma caused by significant force to the head. Following TBI, there are both reparative and degenerative mechanisms that lead to an inflammatory environment. Within minutes of injury, pro-inflammatory cytokines are released. The pro-inflammatory cytokine Il-1β is one such cytokine that exacerbates the tissue damage caused by TBI. TBI may cause significant damage to vital components to the brain, including the blood–brain barrier. Il-1β causes DNA fragmentation and apoptosis, and together with TNF-α may cause damage to the blood–brain barrier and infiltration of leukocytes.
Aging is often associated with cognitive impairment and increased propensity for developing neurodegenerative diseases, such as Alzheimer's disease. In the aged brain alone, without any evident disease, there are chronically increased levels of pro-inflammatory cytokines and reduced levels of anti-inflammatory cytokines. The homeostatic imbalance between anti-inflammatory and pro-inflammatory cytokines in aging is one factor that increasing the risk for neurodegenerative disease. Additionally, there is an increased number of activated microglia in aged brains, which have increased expression of major histocompatibility complex II (MHC II), ionized calcium binding adaptor-1 (IBA1), CD86, ED1 macrophage antigen, CD4, and leukocyte common antigen. These activated microglia decrease the ability for neurons to undergo long term potentiation (LTP) in the hippocampus and thereby reduce the ability to form memories.
Role in Neurodegenerative Disease
Alzheimer's disease historically has been characterized by two major hallmarks: neurofibrillary tangles and amyloid-beta plaques. Neurofibrillary tangles are insoluble aggregates of tau proteins, and amyloid-beta plaques are extracellular deposits of the amyloid-beta protein. Current thinking in Alzheimer's Disease pathology goes beyond these two typical hallmarks to suggest that a significant portion of neurodegeneration in Alzheimer's is due to neuroinflammation. Activated microglia are seen in abundance in post-mortem AD brains. Current thought is that in the presence of inflammatory cytokines activated microglia cannot phagocytose amyloid-beta, which may contribute to plaque accumulation as opposed to clearance. Additionally, the inflammatory cytokine IL-1β is upregulated in Alzheimer's disease and is associated with decreases of synaptophysin and consequent synaptic loss. Further evidence that inflammation is associated with disease progression in Alzheimer's disease, is that persons that take non-steroidal anti-inflammatory drugs (NSAIDs) regularly have been associated with reduced Alzheimer's disease later in life.
The leading hypothesis of Parkinson's disease progression includes neuroinflammation as a major component. This hypothesis, known as “Braak's Hypothesis,” stipulates that Stage 1 of Parkinson's disease begins in the gut, as evidenced by a large amount of cases that begin with constipation. The inflammatory response in the gut may play a role in alpha-synuclein (α-Syn) aggregation and misfolding, a characteristic of Parkinson's disease pathology. If there is a balance between good bacteria and bad bacteria in the gut, the bacteria may remain contained to the gut. However, dysbiosis of good bacteria and bad bacteria may cause a “leaky” gut, creating an inflammatory response. This response aids α-Syn misfolding and transfer across neurons, as the protein works its way up to the CNS. The brainstem is vulnerable to inflammation, which would explain Stage 2 of Braak's hypothesis, including sleep disturbances and depression. In Stage 3 of the hypothesis, the inflammation affects the substantia nigra, the dopamine producing cells of the brain, beginning the characteristic motor deficits of Parkinson's disease. Stage 4 of Parkinson's disease includes deficits caused by inflammation in key regions of the brain that regulate executive function and memory. As evidence supporting Braak's hypothesis, patients in Stage 3 (motor deficits) that are not experiencing cognitive deficits already show that there is neuroinflammation of the cortex. This suggests that neuroinflammation may be a precursor to the deficits seen in Parkinson's disease.
Multiple sclerosis is a very common neuroinflammatory disease. It is characterized by demyelination and neurodegeneration, which contribute to the common symptoms of cognitive deficits, limb weakness, and fatigue. In multiple sclerosis, inflammatory cytokines disrupt the blood–brain barrier and allow for the migration of peripheral immune cells into the central nervous system. When they have migrated into the central nervous system, B Cells and plasma cells produce antibodies against the myelin sheath on neurons, degrading the myelin and slowing conduction in the neurons. Additionally, T Cells may enter through the blood–brain barrier, be activated by local antigen presenting cells, and attack myelin sheath. This has the same effect of degenerating the myelin and slowing conduction. As in other neurodegenerative diseases, activated microglia produce inflammatory cytokines that contribute to the widespread inflammation. It has been shown that inhibiting microglia decreases the severity of multiple sclerosis.
Role as a Therapeutic Target
Because neuroinflammation has been associated with a variety of neurodegenerative diseases, there is increasing interest to determine whether reducing inflammation will reverse neurodegeneration. Inhibiting inflammatory cytokines, such as IL-1β, decreases neuronal loss seen in neurodegenerative diseases. Current treatments for multiple sclerosis include interferon-B, Glatiramer actetate, and Mitoxantrone, which function by reducing or inhibiting T Cell activation, but have the side effect of systemic immunosuppression  In Alzheimer's disease, the use of non-steroidal anti-inflammatory drugs decreases the risk of developing the disease. Current treatments for Alzheimer's disease include NSAIDs and glucocorticoids. NSAIDs function by blocking conversion of prostaglandin H2 into other prostaglandins (PGs) and thromboxane (TX). Prostoglandins and thromboxane act as inflammatory mediators and increase microvascular permeability.
Exercise is a promising mechanism of prevention and treatment for various diseases characterized by neuroinflammation. Aerobic exercise is used widely to reduce inflammation in the periphery. Exercise has been shown to decreases proliferation of microglia in the brain, decrease hippocampal expression of immune-related genes, and reduce expression of inflammatory cytokines such as TNF-α.
- Gendelman, Howard (2002). "Neural immunity: Friend or foe?". Journal of NeuroVirology 8: 474–479. doi:10.1080/13550280290168631.
- Sarma, Jayasri (July 2013). "Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology". J. Neurovirol. 20: 122–136. doi:10.1007/s13365-013-0188-4.
- t' Hart, Bert; Wilfred Dunnen (June 2013). "Commentary on Special Issue: CNS Diseases and the Immune System". J Neuroimmune Pharmacology 8: 757–759. doi:10.1007/s11481=013-9486-0.
- Streit, Wolfgang (July 2004). "Microglia and neuroinflammation: a pathological perspective". Journal of Neuroinflammation 1: 14. doi:10.1186/1742-2094-1-14.
- Mayer, Cynthia (July 2013). "Traumatic Brain Injury, Neuroinflammation, and Post-Traumatic Headaches". Headaches Current. doi:10.1111/head.12173.
- Garden, Gwen (2013). "Epigenetics and the Modulation of Neuroinflammation". Neurotherapeutics 10: 782–788. doi:10.1007/s13311-013-0207-4.
- Ramesh, Geeta (July 2013). "Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain". Mediators of Inflammation 2013: 1–20. doi:10.1155/2013/480739.
- Gomes da Silva, Sergio (2013). "RESEARCH Open Access Exercise-induced hippocampal anti-inflammatory response in aged rats". Journal of Neuroinflammation.
- Kohman, Rachel (September 2013). "Exercise reduces activation of microglia isolated from hippocampus and brain of aged mice". Journal of Neuroinflammation 10: 114. doi:10.1186/1742-2094-10-114.
- Lynch, Marina (2010). "Age-related neuroinflammatory changes negatively impact on neuronal function". Frontiers in Aging Neuroscience 1. doi:10.3389/neuro.24.006.2009.
- Meraz-Rios, Marco (August 2013). "Inflammatory process in Alzheimer's Disease". Frontiers in Integrative Neuroscience 7. doi:10.3389/fnint.2013.00059.
- Tansey, Malu; Tamy C Frank-Cannon (November 2009). "Does neuroinflammation fan the flame in neurodegenerative diseases?". Molecular Neurodegeneration 4: 47. doi:10.1186/1750-1326-4-47.
- Tansey, Malu (May 2012). "Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson's Disease?". Curr Neurol Neurosci Rep 12: 350–358. doi:10.1007/s11910-012-0283-6.
- Zindler, Eva (December 2010). "Neuronal injury in chronic CNS inflammation". Best Practice & Research Clinical Anaesthesiology 24: 551–562. doi:10.1016/j.bpa.2010.11.001.
- McPherson, Rhoanne (2013). "Adaptive Immune Responses in CNS Autoimmune Disease: Mechanisms and Therapeutic Opportunities". J Neuroimmune Pharmacol 8: 774–790. doi:10.1007/s11481-013-9453-9.
Maggi P, Macri SM, Gaitan MI, et al. The formation of inflammatory demyelinated lesions in cerebral white matter. Ann Neurol 2014;76:594–608.